Editing the Genome to Cure Genetic Disease

Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer. Our aim: to transform the lives of patients and families affected by genetic disease.

Social Media

In the spirit of giving for the holiday season, we encourage you to donate to @FightBlindness, a great organization and a cause we are passionate about #CasebiaCares https://t.co/kx1XedP4aL

A successful #ASH18! Here is Casebia's @guenishi with poster "#Genomeediting via #NHEJ Targeted Integration Retains Engraftment Potential of Edited Human HSCs" this weekend.

See us on Twitter